Oxurion NV

📍 Leuven, Belgium👥 46 employees💰 Last funded Aug 2006
Biotechnology Research🌐 oxurion.com
Website LinkedIn
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Belgium
1
Frequently asked questions
Who invested in Oxurion NV?
Oxurion NV has 1 investors on record on gritt.io.
When did Oxurion NV last raise funding?
The most recent investment in Oxurion NV recorded on gritt.io was in August 2006.
What industry is Oxurion NV in?
Oxurion NV operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Oxurion NV based?
Oxurion NV is headquartered in Leuven, Belgium.